HONG KONG, Sept. 6, 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ("Golden Meditech", together with its subsidiaries collectively as the "Group", - 801.HK; 910801.TW), which embodies a leading medical devices enterprise, a major brand name in haematology hospital and the largest stem cell cord blood banking operator in China, is pleased to announce the launch of its Taiwan representative office today.
With a track record in China for establishing the largest stem cell cord blood banking corporation, developing a premium hospital service business, and now, building a cross-straits healthcare enterprise, Mr. Kam Yuen, Chairman and CEO of Golden Meditech, in known as a pioneer in China's healthcare industry. With his remarkable insights and ability to stay ahead of industry trends while having the attention and tenacity as an entrepreneur, Mr. Kam has set his sight on the substantial opportunities in Taiwan's medical and bio-tech industries. The Group has already set foot in Taiwan via issuing Taiwan Depositary Receipts ("TDR") on the Taiwan Stock Exchange in January 2011. Mr. Kam is of the view that the launch of Economic Cooperation Framework Agreement ("ECFA") and the policy allowing for easier access between the straits will foster the development of premium healthcare service sector. Whereas Taiwan has readily accessible medical expertise and resources, with the launch of the new Taiwan representative office, the Group will be able to better leverage its operative advantage, expand its industry reach and create greater opportunities with its Taiwan counterpart for greater growth.
Golden Meditech is the first and one the largest blood-related medical device manufacturers in China with its key product, the Autologous Blood Recovery System ("ABRS") accounting for 80% share of the top-tier hospital market. China's ongoing medical reform has created an excellent opportunity for the Group as a pioneer in the areas of h